Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Widschwendter M et al. - The use of serum ER-alpha and ER-beta bioactivity assays as clinical tools in the management of breast cancer warrants further research. Future studies will dictate whether surrogate markers of ER-alpha and ER-beta bioactivity will provide a means to monitor the efficacy of anti-endocrine, adjuvant and chemopreventive strategies.

Related Articles

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 11/30/09    Relevance Score: 74%

Second solid cancers after radiotherapy for breast cancer in SEER cancer registries
British Journal of Cancer, 11/30/09    Relevance Score: 72%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09    Relevance Score: 72%

Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: The UK MARIBS study
Breast Cancer Research, 11/17/09    Relevance Score: 71%

Breast-feeding the last born child and risk of ovarian cancer
Cancer Causes and Control, 11/16/09    Relevance Score: 71%

Today in Breast...keeping you current

Circulating Carotenoids, Mammographic Density, and Subsequent Risk of Breast Cancer
Cancer Research, 12/18/09

Should routine screening by mammography be replaced by a more selective service of risk assessment/risk management?
Women's Health, 12/18/09

Nipple discharge screening
Women's Health, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address